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Articles
Estimation of the global prevalence and burden of 
obstructive sleep apnoea: a literature-based analysis
Adam V Benjafield, Najib T Ayas, Peter R Eastwood, Raphael Heinzer, Mary S M Ip, Mary J Morrell, Carlos M Nunez, Sanjay R Patel, Thomas Penzel, 
Jean-Louis D Pépin, Paul E Peppard, Sanjeev Sinha, Sergio Tufik, Kate Valentine, Atul Malhotra
Summary
Background There is a scarcity of published data on the global prevalence of obstructive sleep apnoea, a disorder 
associated with major neurocognitive and cardiovascular sequelae. We used publicly available data and contacted key 
opinion leaders to estimate the global prevalence of obstructive sleep apnoea.
Methods We searched PubMed and Embase to identify published studies reporting the prevalence of obstructive 
sleep apnoea based on objective testing methods. A conversion algorithm was created for studies that did not use 
the American Academy of Sleep Medicine (AASM) 2012 scoring criteria to identify obstructive sleep apnoea, 
allowing determination of an equivalent apnoea-hypopnoea index (AHI) for publications that used different criteria. 
The presence of symptoms was not specifically analysed because of scarce information about symptoms in the 
reference studies and population data. Prevalence estimates for obstructive sleep apnoea across studies using 
different diagnostic criteria were standardised with a newly developed algorithm. Countries without obstructive 
sleep apnoea prevalence data were matched to a similar country with available prevalence data; population similarity 
was based on the population body-mass index, race, and geographical proximity. The primary outcome was 
prevalence of obstructive sleep apnoea based on AASM 2012 diagnostic criteria in individuals aged 30–69 years (as 
this age group generally had available data in the published studies and related to information from the UN for 
all countries).
Findings Reliable prevalence data for obstructive sleep apnoea were available for 16 countries, from 17 studies. Using 
AASM 2012 diagnostic criteria and AHI threshold values of five or more events per h and 15 or more events per h, we 
estimated that 936 million (95% CI 903–970) adults aged 30–69 years (men and women) have mild to severe 
obstructive sleep apnoea and 425 million (399–450) adults aged 30–69 years have moderate to severe obstructive sleep 
apnoea globally. The number of affected individuals was highest in China, followed by the USA, Brazil, and India.
Interpretation To our knowledge, this is the first study to report global prevalence of obstructive sleep apnoea; with 
almost 1 billion people affected, and with prevalence exceeding 50% in some countries, effective diagnostic and 
treatment strategies are needed to minimise the negative health impacts and to maximise cost-effectiveness.
Funding ResMed.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Introduction
Obstructive sleep apnoea is a common disorder that can 
present with or without symptoms and is accompanied 
by major neurocognitive and cardiovascular sequelae.1–3 
At present, care of patients with obstructive sleep apnoea 
varies by country and depends on a patient’s symptoms. 
In well resourced settings, considerable efforts are being 
made to diagnose and treat individuals with obstructive 
sleep apnoea, but available data suggest that most cases 
of obstructive sleep apnoea remain undiagnosed and 
untreated, even in developed countries. In developing 
countries, there is generally little awareness of 
obstructive sleep apnoea, and diagnostic and treatment 
options are often not available or have not been adapted 
for resource-poor settings.4 Because of the multifactorial 
and social consequences of obstructive sleep apnoea, the 
disorder is associated with a high economic and societal 
burden. In 2015, the cost of diagnosing and treating 
obstructive sleep apnoea in the USA was approximately 
US$12·4 billion.5 The global cost of diagnosing and 
treating obstructive sleep apnoea has not been estimated 
because information about global prevalence is required 
first.
Evidence suggests that obstructive sleep apnoea is an 
important contributor to poor health outcomes and that 
treatment of this condition is generally beneficial in 
minimising the associated adverse clinical outcomes and 
improving sleep-related quality of life.6 Thus, focusing on 
effective treatment of obstructive sleep apnoea might be 
one approach for reducing associated health-care costs 
and the negative impact of the condition, such as the 
cognitive impact of sleepiness.7,8 Additionally, given the 
shift in focus from issues around malnutrition and basic 
hygiene towards chronic health conditions, such as 
the obesity pandemic and its associated metabolic 
complications,9–12 the ageing population demographic,13 
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and the association between obstructive sleep apnoea 
and various non-communicable diseases,14 obstructive 
sleep apnoea is likely to be a rising global problem over 
the coming years.15,16
Planning for effective diagnosis and management 
strategies requires accurate and country-specific 
estimates of disease prevalence. In 2007, WHO 
estimated that more than 100 million individuals were 
affected by obstructive sleep apnoea worldwide,17 but 
this estimate was acknowledged to be only an 
approximation based on data available at the time. In 
this study we used a new approach and the latest 
publicly available data to estimate the global prevalence 
of obstructive sleep apnoea. We aimed to estimate the 
total number of affected individuals around the world 
and the proportion of those with moderate or severe 
obstructive sleep apnoea because positive airway 
pressure is recommended in all patients with excessive 
sleepiness, impaired sleep-related quality of life, and 
comorbid hypertension, which are more likely with an 
apnoea-hypopnoea index (AHI) of 15 or more events 
per h.18 The aim of our analysis was to raise awareness 
of the global burden of obstructive sleep apnoea by 
providing data to help guide strategies and health 
policies to address this important health and societal 
problem, and to highlight substantial gaps in rigorously 
assessed obstructive sleep apnoea prevalence data that 
are currently unavailable for much of the global 
population. These gaps should be of great concern 
because of the wide-ranging negative sequelae of 
obstructive sleep apnoea.
Methods
Search strategy and selection criteria
We searched PubMed and Embase to identify prevalence 
studies of obstructive sleep apnoea done in the general or 
community population, in adults (aged 18 years and 
older), where obstructive sleep apnoea was measured 
objectively with a sleep study. We selected general 
population prevalence studies rather than those done in 
selected groups on the basis of concomitant diseases or 
those done in clinical settings where referral bias could be 
an important limitation. Only studies that used objective 
testing (rather than questionnaires) to diagnose 
obstructive sleep apnoea were included in our analysis. 
This included use of either home sleep testing (including 
airflow and oximetry) or in-laboratory polysomnography 
and reporting the AHI. We had no specific requirement 
for how obstructive sleep apnoea symptoms were 
evaluated or reported. The timeframe for studies was not 
limited in the search and the key words used in all 
combinations were “sleep disordered breathing”, “sleep 
apnoea”, “sleep apnoea syndrome”, “obstructive”, 
“prevalence”, and “population”. The original search was 
done in April, 2017, and then rechecked in February, 2019 
(no new papers were identified in the second search). 
Reference lists of identified papers were manually 
reviewed. We applied no language exclusions so papers 
published in other languages were translated into English. 
Authors of the major studies identified were invited to 
collaborate. Our estimates focused on individuals aged 
30–69 years because data for this group were generally 
available from the published studies and related to 
information from the UN for all countries. Therefore, the 
resulting prevalence estimates relate specifically to a 
subset of the global population aged 30–69 years.
Data collection and analysis
For studies that did not use the American Academy of 
Sleep Medicine (AASM) 2012 scoring criteria19 to identify 
obstructive sleep apnoea, we created a conversion 
algorithm based on the study by Duce and colleagues20; 
Research in context
Evidence before this study
Despite increasing recognition of obstructive sleep apnoea as 
a contributor to poor health outcomes, our literature searches 
identified a scarcity of data about global prevalence of obstructive 
sleep apnoea. We searched PubMed and Embase using search 
terms of “adult”, “sleep disordered breathing”, “sleep apnoea”, 
“sleep apnoea syndrome”, “obstructive”, “prevalence”, and 
“population”, with no limits on timeframe nor any language 
restrictions. The original search was done in April, 2017, and then 
rechecked in February, 2019 (no new papers were identified in the 
second search). Relevant and local prevalence data are important 
to facilitate implementation of effective and efficient strategies 
for diagnosis and management of obstructive sleep apnoea.
Added value of this study
To the best of our knowledge, this is the first study to report a 
global estimate of obstructive sleep apnoea prevalence and to 
estimate the number of individuals affected by this condition 
worldwide. Nearly 1 billion adults aged 30–69 years worldwide 
were estimated to have obstructive sleep apnoea, with and 
without symptoms, based on an apnoea-hypopnoea index 
(AHI) cutoff value of five or more events per h, with 425 million 
(>45%) of these individuals having an AHI of 15 or more events 
per h (defined as a moderate to severe disorder requiring 
treatment). Wide geographical variation exists in the 
prevalence of obstructive sleep apnoea, with prevalence 
exceeding 50% in some countries.
Implications of all the available evidence
Given the high burden of obstructive sleep apnoea worldwide, 
health-care systems need to adopt effective diagnostic and 
management strategies so that the negative health impacts 
of obstructive sleep apnoea can be minimised.
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this approach allowed us to determine an equivalent AHI 
for publications that used different criteria:21
Thus, we were able to report AHI figures based on the 
AASM 1999, AASM 2007, and AASM 2012 criteria, even 
if these criteria were not used in the original studies.19,22 
The main differences between the criteria relate to 
scoring of hypopnoeas (table 1).
An algorithm was developed in consultation with all 
authors to estimate global prevalence of obstructive 
sleep apnoea in individuals aged 30–69 years from the 
available published data. Prevalence for men and 
women was estimated separately and then combined to 
provide total prevalence. For countries with published 
prevalence estimates for obstructive sleep apnoea, 
these data were used. If no country-specific estimates 
were available, we matched countries without preva-
lence data to similar countries with prevalence data; 
determination of country population similarity was 
based on the population body-mass index (BMI; within 
1 kg/m²), race (smallest difference in proportion of 
white, black, and Asian populations between the 
country being matched and the reference country or 
countries), and geo graphical proximity based on 
distance (appendix p 1). Age, sex, BMI, and race were 
used to match countries because these factors are 
clinically recognised to affect prevalence of obstructive 
sleep apnoea and these data were available for all 
countries. We obtained data on global estimates of BMI 
from the WHO Global Health Observatory data 
repository, data on race from the Central Intelligence 
Agency’s World Factbook, and data on population-based 
age and sex from the UN World Population Prospects 
2015. We evaluated the performance of our estimation 
procedure by comparing its performance in countries 
where prevalence data were available. Goodness of fit 
for these comparisons is shown in the appendix 
(pp 1–3). In two studies, the overall number of 
individuals used for the obstructive sleep apnoea 
prevalence estimates were reported, but not sex-
specific numbers. In these cases, we assumed a 
50:50 distribution between the sexes.
Our confidence intervals for the global estimate 
incorporate the sampling variability in the estimates of 
Hypopnoea criteria
1999 guideline ≥50% decrease in flow OR a clear reduction in flow that 
does not reach ≥50% AND is associated with either an 
oxygen desaturation of ≥3% or an arousal
2007 guideline ≥30% decrease in flow from baseline with an associated 
oxygen desaturation of ≥4%
2012 guideline ≥30% decrease in flow from baseline with an associated 
oxygen desaturation of ≥3% OR an associated arousal
Table 1: Differences in hypopnea scoring rules between American 
Academy of Sleep Medicine guidelines19,22
Sample size Year Age range, 
years
Men (%) Scoring criteria Nasal pressure AHI ≥5 events per h AHI ≥15 events per h
Men Women Men Women
Australia24 380 2008 40–65 73% AASM 2012 Yes 25·5% 23·5% 4·7% 4·9%
Brazil25 1042 2010 20–80 45% AASM 2007 Yes 46·5% 30·6% 24·8% 9·6%
China38 3648 2005 ≥20 50% Chicago 1999 Unspecified 24·2% 24·2% 9·5% 9·5%
Germany39 1208 2018 20–81 54% AASM 2007 Yes 59·4% 33·2% 29·7% 13·2%
Hong Kong27 153 2001 30–60 100% AASM 2007 No 8·8% ·· 5·3% ··
Hong Kong28 106 2004 30–60 0% AASM 2007 No ·· 3·7% ·· 1·9%
Iceland29 415 2016 40–65 ·· AASM 2007 Yes 13·3% 10·8% 10·6% 4·8%
India30 365 2009 30–65 ·· Chicago 1999 Yes 13·5% 6·1% 5·5% 6·1%
Japan32 322 2008 23–59 ·· AASM 2012 Yes 59·7% ·· 22·3% ··
New Zealand31 364 2009 30–59 ·· AASM 2007 Yes 12·5% 3·4% 3·9% 0·2%
Norway33 518 2011 30–65 55% AASM 2007 No 21·0% 13·0% 11·0% 6·0%
Poland34 676 2008 41–72 54% AASM 2007 Yes 36·2% 18·4% 15·8% 7·6%
South Korea35 457 2004 40–69 69% AASM 2007 No 27·1% 16·8% 10·1% 4·7%
Singapore36 242 2016 21–79 50% AASM 2007 Yes 62·3% 62·3% 26·1% 26·1%
Singapore36 242 2016 21–79 50% AASM 2012 Yes 70·8% 70·8% 30·5% 30·5%
Spain37 2148 2001 30–70 49% AASM 2007 No 26·2% 28·0% 14·2% 7·0%
Switzerland23 2121 2015 40–85 48% AASM 2012 Yes 83·8% 60·8% 49·7% 23·4%
USA26 1520 2013 30–70 55% AASM 2007 Yes 33·9% 17·4% 13·0% 6·0%
Based on two different apnoea-hypopnoea index (AHI) cutoff values.
Table 2: Studies reporting country-specific data on obstructive sleep apnoea prevalence
See Online for appendix
Alternative Scoring 
Rule Conversion 
Factor 
Reference study result × Duce et al
result for alternative scoring rule
Duce et al result for reference 
study scoring rule
=
For global estimates of BMI see 
http://apps.who.int/gho/data/
node.main.A904?lang=en
For the CIA World Factbook see 
https://www.cia.gov/library/
publications/resources/the-
world-factbook/
For the UN World Population 
Prospects see https://esa.un.
org/unpd/wpp/
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obstructive sleep apnoea prevalence from 17 studies, 
but do not incorporate the modelling error in estimating 
each country’s prevalence estimate (since the algorithm 
was not a statistical model). A sensitivity analysis based 
on a regression model is described below, which does 
incorporate modelling error into the confidence 
interval. The sampling variability confidence interval 
assesses how the variability in each study’s prevalence 
estimate affects the global obstructive sleep apnoea 
estimate. Specifically, the global estimate can be defined 
as follows:
where Ni is the population size of the ith subgroup 
(each subgroup is a sex in a specific country), K=386 
(193 countries multiplied by 2 for both sexes) and pi is the 
obstructive sleep apnoea prevalence estimate applied to 
the ith subgroup. Since M=32 prevalence estimates were 
applied to the 386 population sizes (M is the number of 
reference prevalence estimates; 15 studies produced 
estimates for men and women, and two studies produced 
a single-sex estimate), the estimate can be rewritten by 
summing the population sizes of all subgroups to which 
each estimate was applied:
where Mk is the total population size to which the kth 
obstructive sleep apnoea prevalence estimate was 
applied. The obstructive sleep apnoea prevalence 
estimate pk has variance pk(1 − pk)/nk, where nk is the 
number of individuals used to estimate pk. The 
individuals used in each prevalence estimate are 
Figure 1: Estimated prevalence of obstructive sleep apnoea based on different scoring rules
AASM=American Academy of Sleep Medicine. AHI=apnoea-hypopnoea index.
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Figure 2: Top ten countries with the highest estimated number of individuals with obstructive sleep apnoea based on the American Academy of Sleep 
Medicine 2012 criteria19
AHI=apnoea-hypopnoea index. 
Russia
AHI ≥5 events per h: 40 million
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AHI ≥15 events per h: 29 million
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AHI ≥5 events per h: 42 million
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AHI ≥15 events per h: 12 million
Brazil
AHI ≥5 events per h: 49 million
AHI ≥15 events per h: 25 million
USA
AHI ≥5 events per h: 54 million
AHI ≥15 events per h: 24 million
Japan
AHI ≥5 events per h: 22 million
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Germany
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Figure 3: Global heat map of estimated prevalence of obstructive sleep apnoea (AHI five or more events per h) for each country
AHI=apnoea-hypopnoea index.
7·8% 77·2%
Figure 4: Global heat map of estimated prevalence of obstructive sleep apnoea (AHI 15 or more events per h) for each country
AHI=apnoea-hypopnoea index.
3·0% 36·6%
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independent; thus, the variance of the global estimate is 
Var(X), and the 95% CI is X ± 1∙96√Var(X):
As a sensitivity analysis, an over-dispersed logistic 
regression model was fit to data from the prevalence 
estimate studies (each sex was modelled separately). 
The prevalence estimate of obstructive sleep apnoea was 
treated as the dependent variable; BMI and proportion 
of the white population were treated as continuous 
independent variables, continent was treated as a 
categorical independent variable, and an over-dispersion 
factor was added to the model to account for the wide 
variability across countries. This model then allowed for 
construction of a 95% CI that incorporated sampling 
variability in each study as well as the modelling errors 
in predicting each country’s prevalence estimate. Since 
we found no studies of obstructive sleep apnoea 
prevalence in Africa, Africa was grouped with Oceania 
(similar estimates were obtained if Africa was grouped 
with Europe, North America, or South America). 
Statistical analyses were done with R software, 
version 3.3.
Role of the funding source
This work represents an academic and industry 
partnership. The study sponsor was involved in study 
design, data collection, data analysis, data interpretation, 
and writing of the report. All authors had full access to all 
the data and collectively made the decision to submit for 
publication.
Results
17 articles were included in the analyses (table 2).23–39 
Reliable prevalence estimates were obtained on the basis 
of available data for 16 of 193 countries in the world; 
prevalence estimates for the remaining countries were 
extrapolated as described above.
Using an AHI criterion of five or more events per h 
and the AASM 2012 criteria, an estimated 936 million 
(95% CI 903–970) individuals aged 30–69 years (men 
and women) worldwide were found to have obstructive 
sleep apnoea; the corresponding figure for an AHI of 
15 or more events per h was 425 million (399–450; 
figure 1). The logistic regression model yielded a global 
obstructive sleep apnoea (AHI of five or more events 
per h) estimate of 730 million (618–842). Numbers of 
affected individuals were lower when the AASM 2007 
criteria were applied and highest with the 1999 AASM 
criteria (figure 1). The estimated number of individuals 
with obstructive sleep apnoea was highest in China, 
followed by the USA, Brazil, and India; other countries 
in the top ten for the number of individuals with 
obstructive sleep apnoea were Pakistan, Russia, Nigeria, 
Population aged 
30–69 years
AHI ≥5 events per h AHI ≥15 events per h
Afghanistan 8 429 549 3 040 802 (36·1%) 1 171 173 (13·9%)
Albania 1 357 655 850 606 (62·7%) 467 163 (34·4%)
Algeria 16 435 999 8 807 804 (53·6%) 3 389 447 (20·6%)
Angola 6 091 184 3 670 768 (60·3%) 1 392 665 (22·9%)
Antigua and Barbuda 42 485 10 181 (24·0%) 3010 (7·1%)
Argentina 19 016 260 5 443 083 (28·6%) 2 490 616 (13·1%)
Armenia 1 513 141 768 580 (50·8%) 380 977 (25·2%)
Aruba 56 900 13 896 (24·4%) 2736 (4·8%)
Australia 12 110 362 2 966 536 (24·5%) 581 348 (4·8%)
Austria 4 601 766 2 241 500 (48·7%) 1 306 180 (28·4%)
Azerbaijan 4 622 249 1 975 143 (42·7%) 1 116 199 (24·1%)
Bahamas 189 235 45 418 (24·0%) 13 296 (7·0%)
Bahrain 679 684 496 137 (73·0%) 214 997 (31·6%)
Bangladesh 62 623 678 5 983 546 (9·6%) 3 381 433 (5·4%)
Barbados 147 687 35 406 (24·0%) 10 439 (7·1%)
Belarus 5 155 802 1 068 785 (20·7%) 708 401 (13·7%)
Belgium 5 917 763 1 801 591 (30·4%) 931 859 (15·7%)
Belize 128 677 30 922 (24·0%) 8982 (7·0%)
Benin 3 096 334 1 865 770 (60·3%) 707 741 (22·9%)
Bhutan 310 278 137 202 (44·2%) 51 229 (16·5%)
Bolivia 3 816 716 1 592 038 (41·7%) 812 240 (21·3%)
Bosnia and Herzegovina 2 185 242 1 075 346 (49·2%) 626 902 (28·7%)
Botswana 826 982 410 657 (49·7%) 152 857 (18·5%)
Brazil 98 118 248 48 729 844 (49·7%) 25 481 720 (26·0%)
Brunei 205 295 158 488 (77·2%) 69 390 (33·8%)
Bulgaria 4 008 872 1 943 121 (48·5%) 1 132 070 (28·2%)
Burkina Faso 4 632 827 434 092 (9·4%) 250 858 (5·4%)
Burundi 2 912 564 276 938 (9·5%) 157 378 (5·4%)
Cape Verde 181 546 99 348 (54·7%) 40 543 (22·3%)
Cambodia 5 791 914 537 020 (9·3%) 314 087 (5·4%)
Cameroon 6 304 367 2 313 265 (36·7%) 929 799 (14·7%)
Canada 19 273 831 4 721 439 (24·5%) 925 209 (4·8%)
Central African Republic 1 443 196 267 053 (18·5%) 100 838 (7·0%)
Chad 3 268 977 1 384 009 (42·3%) 586 746 (17·9%)
Chile 8 809 775 1 671 811 (19·0%) 954 857 (10·8%)
China 744 511 252 175 704 655 (23·6%) 65 516 990 (8·8%)
Colombia 22 074 042 10 953 050 (49·6%) 5 721 534 (25·9%)
Comoros 235 465 116 985 (49·7%) 43 546 (18·5%)
Congo 1 344 345 498 468 (37·1%) 191 977 (14·3%)
Costa Rica 2 237 598 548 017 (24·5%) 107 424 (4·8%)
Côte d’Ivoire 6 367 814 3 835 249 (60·2%) 1 453 687 (22·8%)
Croatia 2 312 850 473 908 (20·5%) 276 871 (12·0%)
Cuba 6 188 715 3 096 611 (50·0%) 1 633 275 (26·4%)
Curacao 81 939 27 359 (33·4%) 8404 (10·3%)
Cyprus 603 532 175 258 (29·0%) 101 317 (16·8%)
Czech Republic 5 973 449 1 726 302 (28·9%) 994 554 (16·6%)
Democratic Republic of the Congo 19 722 105 1 870 886 (9·5%) 1 066 027 (5·4%)
Denmark 2 927 893 1 430 836 (48·9%) 833 901 (28·5%)
Djibouti 310 917 115 180 (37·0%) 44 360 (14·3%)
Dominican Republic 4 125 868 2 055 301 (49·8%) 1 078 533 (26·1%)
Ecuador 6 442 389 2 682 640 (41·6%) 1 366 852 (21·2%)
(Table 3 continues on next page)
Var(X) =Σ M2 Var(pk)k
M
k = 1
=
Σ M2 pk(1 – pk)k
M
k = 1
nk
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Germany, France, and Japan (figure 2), which 
predominantly reflects the overall size of the population 
of these countries. When expressed as a prevalence, the 
obstructive sleep apnoea burden for each country is 
shown as a heat map for an AHI of five or more events 
per h and an AHI of 15 or more events per h (figures 3, 4). 
A summary of the number of affected individuals and 
overall obstructive sleep apnoea prevalence for each 
country, region, or territory is provided in table 3. 
Discussion
Our estimates suggest that nearly 1 billion adults aged 
30–69 years worldwide could have obstructive sleep 
apnoea, and the number of people with moderate to 
severe obstructive sleep apnoea, for which treatment is 
generally recommended, is estimated to be almost 
425 million. To the best of our knowledge, this analysis 
represents the first set of global estimates of the 
prevalence of obstructive sleep apnoea.
Based on the published literature and by matching 
countries based on population demographics where 
specific data were not available, we estimated that almost 
1 billion people worldwide aged between 30–69 years have 
an AHI of five or more events per h. The overall prevalence 
of obstructive sleep apnoea is likely to be higher given that 
the analysis focused only on adults aged 30–69 years and 
we used AASM 2012 criteria rather than the more liberal 
AASM 1999 criteria.22,40 The prevalence of obstructive sleep 
apnoea will be lower in adults younger than 30 years, and 
higher in adults aged 70 years and older, than we have 
estimated in this analysis, since previous publications 
show a linear relationship between age and obstructive 
sleep apnoea prevalence.25 The number of individuals with 
moderate to severe obstructive sleep apnoea, based on an 
AHI of 15 or more events per h, was 425 million. This 
group could be considered the clinically important 
obstructive sleep apnoea population for whom treatment 
would be recommended, even though symptoms were not 
included in our estimate. We found that obstructive sleep 
apnoea prevalence estimates were dependent on the 
respiratory event scoring criteria used, but we focused on 
AASM 201219 because these guidelines are in widespread 
clinical use, and standardised data from different studies 
can be generated with a conversion factor. The optimal 
criteria for scoring is likely to depend on the technology 
used and the clinical outcomes of interest, but these 
variations are subtle compared with the large burden of 
disease that is undiagnosed at present. Based on the 
magnitude of these results, re-evaluation of the current 
AHI thresholds might be prudent when the latest sleep 
study scoring criteria and technologies are used in relation 
to clinical outcomes to identify the thresholds at which 
treatment is most appropriate. In 2007, WHO estimated 
that more than 100 million people worldwide were likely 
to have obstructive sleep apnoea.17 However, to our 
knowledge, this value was acknowledged to be a gross 
approximation based on the data available at the time. We 
Population aged 
30–69 years
AHI ≥5 events per h AHI ≥15 events per h
(Continued from previous page)
Egypt 34 241 981 17 065 251 (49·8%) 9 373 686 (27·4%)
El Salvador 2 385 301 930 046 (39·0%) 518 118 (21·7%)
Equatorial Guinea 269 554 151 455 (56·2%) 62 203 (23·1%)
Eritrea 1 444 877 136 808 (9·5%) 78 120 (5·4%)
Estonia 686 893 141 780 (20·6%) 94 804 (13·8%)
eSwatini 348 096 158 683 (45·6%) 67 383 (19·4%)
Ethiopia 27 021 835 2 555 467 (9·5%) 1 461 244 (5·4%)
Federated States of Micronesia 31 811 7651 (24·1%) 2211 (6·9%)
Fiji 382 118 159 154 (41·7%) 90 765 (23·8%)
Finland 2 894 948 1 458 419 (50·4%) 853 928 (29·5%)
France 32 613 385 23 506 723 (72·1%) 11 836 999 (36·3%)
French Polynesia 133 978 56 102 (41·9%) 32 053 (23·9%)
Gabon 543 329 302 567 (55·7%) 124 000 (22·8%)
Gambia 503 578 303 519 (60·3%) 115 181 (22·9%)
Georgia 2 021 511 510 200 (25·2%) 212 087 (10·5%)
Germany 43 751 645 26 279 946 (60·1%) 14 393 964 (32·9%)
Ghana 8 651 157 3 100 709 (35·8%) 1 251 736 (14·5%)
Greece 5 966 188 1 708 436 (28·6%) 782 555 (13·1%)
Grenada 41 701 17 361 (41·6%) 9899 (23·7%)
Guam 76 175 49 640 (65·2%) 20 063 (26·3%)
Guatemala 5 115 784 2 619 198 (51·2%) 1 303 428 (25·5%)
Guinea 3 554 378 655 324 (18·4%) 247 498 (7·0%)
Guinea-Bissau 544 150 203 608 (37·4%) 78 415 (14·4%)
Guyana 315 281 101 440 (32·2%) 60 003 (19·0%)
Haiti 3 652 569 2 586 019 (70·8%) 1 114 034 (30·5%)
Honduras 2 770 841 1 473 684 (53·2%) 746 876 (27·0%)
Hong Kong 4 377 697 340 901 (7·8%) 229 985 (5·3%)
Hungary 5 445 718 2 104 733 (38·6%) 1 139 523 (20·9%)
Iceland 162 564 25 372 (15·6%) 19 136 (11·8%)
India 534 676 709 51 556 642 (9·6%) 28 831 856 (5·4%)
Indonesia 114 334 042 21 020 883 (18·4%) 7 940 317 (6·9%)
Iran 36 179 787 15 136 458 (41·8%) 7 739 991 (21·4%)
Iraq 10 771 896 2 734 061 (25·4%) 1 303 288 (12·1%)
Ireland 2 447 445 599 525 (24·5%) 117 487 (4·8%)
Israel 3 465 330 848 255 (24·5%) 166 411 (4·8%)
Italy 33 020 571 6 774 829 (20·5%) 3 959 253 (12·0%)
Jamaica 1 176 758 483 534 (41·1%) 274 482 (23·3%)
Japan 67 496 374 22 092 507 (32·7%) 9 435 205 (14·0%)
Jordan 2 636 480 751 598 (28·5%) 413 338 (15·7%)
Kazakhstan 7 774 654 3 779 915 (48·6%) 1 862 950 (24·0%)
Kenya 13 024 588 4 838 661 (37·2%) 1 863 525 (14·3%)
Kiribati 38 538 12 573 (32·6%) 5486 (14·2%)
Kuwait 2 012 453 377 748 (18·8%) 146 612 (7·3%)
Kyrgyzstan 2 226 975 1 170 950 (52·6%) 590 266 (26·5%)
Laos 2 144 108 377 558 (17·6%) 132 705 (6·2%)
Latvia 1 037 979 215 042 (20·7%) 142 707 (13·7%)
Lebanon 2 446 505 709 282 (29·0%) 334 845 (13·7%)
Lesotho 607 425 299 273 (49·3%) 111 379 (18·3%)
Liberia 1 306 827 478 462 (36·6%) 192 392 (14·7%)
Libya 2 692 584 1 437 964 (53·4%) 796 612 (29·6%)
(Table 3 continues on next page)
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believe our approach of a country-imputation algorithm is 
a legitimate attempt to quantitatively synthesise the 
available evidence to estimate the global prevalence of 
obstructive sleep apnoea. Our approach used the major 
known factors that influence prevalence of obstructive 
sleep apnoea by matching on age, sex, BMI, and race, and, 
if required, geographical proximity, to identify the most 
suitable reference study to be applied to a country without 
introducing further assumptions. Both the primary 
country-imputation algorithm and the secondary logistic 
modelling approach led to global estimates that were 
much larger than those previously reported by WHO, 
although they were similar in magnitude to previously 
reported estimates. Increasing prevalence of obstructive 
sleep apnoea globally is consistent with single-country 
trends.26 Various complex reasons probably underlie the 
discrepancy between our estimates and those from WHO 
in 2007, including the more precise methodological 
approach in our study and advances in detection 
technology.41 Various population and population health 
factors are also likely to have had a role. Obstructive sleep 
apnoea is common in patients with high BMI26,42 and with 
increasing age.26,37,42,43 Therefore, the worldwide obesity 
epidemic and the ageing population demographic are 
likely to contribute to the rising global prevalence of 
obstructive sleep apnoea. Additionally, the high prevalence 
seen in countries such as China is likely to be due to racial 
and genetic differences in common anatomical features 
that increase the likelihood of obstructive sleep apnoea, 
such as a narrower airway.44 The increasing burden of 
non-communicable diseases, such as diabetes, and more 
sedentary lifestyles could also have a role in the rising 
global prevalence of obstructive sleep apnoea.45
Our analysis highlights the importance of considering 
how the burden of obstructive sleep apnoea should be 
managed. In countries where a diagnosis of obstructive 
sleep apnoea is less well recognised, education and 
advocacy are required to inform both patients and health-
care providers about this condition and its associated 
complications.4,46 In settings where technologies for 
diagnosing and treating obstructive sleep apnoea are 
not available, efforts to leverage alternative technologies 
to facilitate provision of cost-effective care need to 
be considered, along with strategies to improve 
accessibility. For example, wearable technologies, validated 
questionnaires, and connected devices could be used to 
optimise diagnosis.47,48 In this context, efforts are underway 
to try to diagnose obstructive sleep apnoea with simple 
devices that can be used anywhere in the world.49,50 
Moreover, cloud-based technologies allow centralised 
reading and scoring of sleep tests so that local expertise is 
no longer needed to deliver appropriate diagnostic care.48,51 
The high estimated global prevalence in this study suggests 
that the development of new and cheaper alternatives to 
diagnose and treat obstructive sleep apnoea are required.
For countries with well resourced health-care systems, 
delivery models whereby many patients can receive 
Population aged 
30–69 years
AHI ≥5 events per h AHI ≥15 events per h
(Continued from previous page)
Lithuania 1 492 888 426 074 (28·5%) 243 247 (16·3%)
Luxembourg 308 327 78 855 (25·6%) 48 029 (15·6%)
Macao 347 288 27 507 (7·9%) 18 609 (5·4%)
Macedonia 1 116 387 561 099 (50·3%) 328 508 (29·4%)
Madagascar 6 863 789 651 925 (9·5%) 370 938 (5·4%)
Malawi 4 141 023 1 743 713 (42·1%) 739 079 (17·8%)
Malaysia 13 270 264 10 244 644 (77·2%) 4 485 349 (33·8%)
Maldives 140 459 104 079 (74·1%) 45 157 (32·1%)
Mali 4 343 219 2 837 614 (65·3%) 1 149 316 (26·5%)
Malta 225 879 79 359 (35·1%) 36 769 (16·3%)
Mauritania 1 252 071 621 950 (49·7%) 231 508 (18·5%)
Mauritius 658 995 328 627 (49·9%) 172 660 (26·2%)
Mexico 52 649 824 9 921 240 (18·8%) 5 655 904 (10·7%)
Moldova 2 144 482 1 116 710 (52·1%) 560 328 (26·1%)
Mongolia 1 238 490 632 863 (51·1%) 267 839 (21·6%)
Montenegro 324 337 98 333 (30·3%) 59 139 (18·2%)
Morocco 14 584 119 6 974 795 (47·8%) 3 472 365 (23·8%)
Mozambique 7 104 990 2 763 293 (38·9%) 1 064 150 (15·0%)
Namibia 773 988 379 296 (49·0%) 141 145 (18·2%)
Nepal 10 032 271 6 585 332 (65·6%) 2 677 534 (26·7%)
Netherlands 9 050 266 4 430 942 (49·0%) 2 582 583 (28·5%)
New Caledonia 125 207 51 992 (41·5%) 29 620 (23·7%)
New Zealand 2 256 063 227 248 (10·1%) 68 590 (3·0%)
Nicaragua 2 282 569 919 626 (40·3%) 518 443 (22·7%)
Niger 4 811 710 463 647 (9·6%) 259 493 (5·4%)
Nigeria 51 068 452 30 766 820 (60·2%) 11 667 219 (22·8%)
North Korea 12 477 221 5 303 362 (42·5%) 2 248 695 (18·0%)
Norway 2 684 446 593 951 (22·1%) 351 443 (13·1%)
Oman 2 028 410 1 110 702 (54·8%) 643 631 (31·7%)
Pakistan 63 098 158 41 569 793 (65·9%) 17 041 309 (27·0%)
Panama 1 685 593 697 036 (41·4%) 396 546 (23·5%)
Papua New Guinea 2 560 672 1 281 720 (50·1%) 676 302 (26·4%)
Paraguay 2 441 919 1 476 456 (60·5%) 745 739 (30·5%)
Peru 12 928 630 6 873 395 (53·2%) 3 482 848 (26·9%)
Philippines 37 976 672 15 791 279 (41·6%) 5 895 648 (15·5%)
Poland 21 519 587 7 554 166 (35·1%) 3 823 093 (17·8%)
Portugal 5 691 681 967 049 (17·0%) 713 458 (12·5%)
Puerto Rico 1 807 598 892 217 (49·4%) 463 203 (25·6%)
Qatar 1 154 042 359 550 (31·2%) 214 436 (18·6%)
Romania 10 861 099 5 223 068 (48·1%) 3 041 952 (28·0%)
Russia 78 239 383 40 203 912 (51·4%) 20 043 199 (25·6%)
Rwanda 3 315 948 1 511 839 (45·6%) 642 777 (19·4%)
Saint Lucia 84 561 27 871 (33·0%) 12 180 (14·4%)
Saint Vincent and the Grenadines 49 135 20 548 (41·8%) 11 735 (23·9%)
Samoa 64 569 21 696 (33·6%) 9509 (14·7%)
São Tomé and Principe 52 190 28 630 (54·9%) 11 691 (22·4%)
Saudi Arabia 14 300 262 3 491 177 (24·4%) 913 235 (6·4%)
Senegal 4 064 706 1 577 592 (38·8%) 607 536 (14·9%)
Serbia 4 730 407 2 343 842 (49·5%) 1 371 614 (29·0%)
Seychelles 47 600 19 944 (41·9%) 11 397 (23·9%)
(Table 3 continues on next page)
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high-quality care without the need for multiple office 
visits with subspecialists need to be considered, along 
with alternative payment models.52 For uncomplicated 
obstructive sleep apnoea, models of care are being 
developed that allow excellent clinical outcomes while 
potentially minimising costs. For example, Antic and 
colleagues53 have shown that primary care physicians 
and nurse practitioners, under appropriate supervision, 
can achieve good outcomes in management of 
obstructive sleep apnoea. With the push towards cost-
effective care across the entire health-care system, 
efficient care delivery models are being increasingly 
discussed52 and resources reallocated to multimorbid 
obstructive sleep apnoea.54 Notably, although the 
diagnosis and treatment of sleep disorders can be viewed 
as a large economic burden, some health economic 
studies have suggested that management of obstructive 
sleep apnoea is not just cost effective but potentially cost 
saving as a result of prevention of major complications.54–56 
Nevertheless, the cost of treatment devices might be an 
important barrier to treatment in low-income and 
middle-income countries. To improve health equity, it 
might be necessary for global health bodies, including 
WHO, the UN, and non-governmental organisations, to 
lobby for provision of treatment devices for obstructive 
sleep apnoea at costs substantially lower than current 
pricing to facilitate access in developing regions.
The findings of our study need to be interpreted in the 
context of various limitations. First, although the goal of 
our analysis was to include as much published data from 
several countries and be as accurate as possible, we found 
no published prevalence data for obstructive sleep apnoea 
for most countries, including no countries from Africa. 
We therefore used techniques designed to provide the best 
estimates possible using available data from groups with 
similar demographic characteristics. This led to the 
reference studies being represented many times because 
of the nature of our country-imputation algorithm (ie, we 
used data from 16 countries to make estimates for 
177 countries worldwide). Although we believe our global 
estimates are robust when compared with the country-
specific extrapolated estimates, individual country 
estimates were needed to generate the global estimate, so 
the country-specific estimates for those countries where 
no prevalence study was previously done should not be 
used in any formal way because these estimates might not 
be as precise as those for countries with available 
prevalence data. Additionally, we have not provided 
specific data for men and women or data about disease 
burden in different age groups. We hope that the data 
gaps identified in our analysis will help encourage more 
scrupulous epidemiological studies, particularly from 
regions where rigorous data are not currently available. 
Our sensitivity analysis, based on a logistic regression of 
the available data, yielded a lower estimate of the 
prevalence of obstructive sleep apnoea than the country-
imputation algorithm (730 million vs 936 million) 
although it still confirmed a high prevalence of obstructive 
sleep apnoea. The logistic regression is lower because 
estimates from countries such as Singapore, Germany, 
and Switzerland are attenuated toward the means of their 
Population aged 
30–69 years
AHI ≥5 events per h AHI ≥15 events per h
(Continued from previous page)
Sierra Leone 1 824 011 684 252 (37·5%) 263 523 (14·4%)
Singapore 3 237 710 2 292 299 (70·8%) 987 502 (30·5%)
Slovakia 3 059 176 1 415 361 (46·3%) 824 991 (27·0%)
Slovenia 1 162 317 632 758 (54·4%) 360 969 (31·1%)
Solomon Islands 183 167 100 926 (55·1%) 41 256 (22·5%)
Somalia 2 669 125 1 138 978 (42·7%) 483 018 (18·1%)
South Africa 20 931 899 8 448 087 (40·4%) 4 765 612 (22·8%)
South Korea 28 715 868 8 164 156 (28·4%) 3 255 814 (11·3%)
South Sudan 3 418 246 1 448 320 (42·4%) 614 029 (18·0%)
Spain 26 158 266 9 195 448 (35·2%) 4 233 728 (16·2%)
Sri Lanka 9 950 827 4 054 922 (40·7%) 1 513 847 (15·2%)
Sudan 12 004 972 1 141 322 (9·5%) 648 692 (5·4%)
Suriname 237 958 98 649 (41·5%) 56 170 (23·6%)
Sweden 4 918 210 836 190 (17·0%) 626 258 (12·7%)
Switzerland 4 518 615 3 269 301 (72·4%) 1 654 232 (36·6%)
Syria 6 085 585 3 204 881 (52·7%) 1 770 598 (29·1%)
Taiwan 13 539 701 3 195 369 (23·6%) 1 191 494 (8·8%)
Tajikistan 2 797 823 1 074 632 (38·4%) 657 685 (23·5%)
Tanzania 14 004 347 5 225 916 (37·3%) 2 012 654 (14·4%)
Thailand 37 728 597 13 743 556 (36·4%) 5 531 503 (14·7%)
Timor Leste 331 218 31 787 (9·6%) 17 873 (5·4%)
Togo 2 088 857 1 259 007 (60·3%) 477 774 (22·9%)
Tonga 34 943 11 485 (32·9%) 5017 (14·4%)
Trinidad and Tobago 699 011 167 969 (24·0%) 48 803 (7·0%)
Tunisia 5 283 180 2 187 476 (41·4%) 1 109 698 (21·0%)
Turkey 35 176 270 3 714 957 (10·6%) 2 797 599 (8·0%)
Turkmenistan 2 163 412 1 136 509 (52·5%) 645 683 (29·8%)
Uganda 8 850 820 3 751 125 (42·4%) 1 590 342 (18·0%)
Ukraine 24 593 547 12 691 100 (51·6%) 7 194 877 (29·3%)
United Arab Emirates 5 433 364 950 096 (17·5%) 360 948 (6·6%)
UK 32 936 962 8 065 555 (24·5%) 1 581 374 (4·8%)
USA 163 246 772 54 131 654 (33·2%) 23 678 109 (14·5%)
Uruguay 1 578 418 386 221 (24·5%) 75 813 (4·8%)
Uzbekistan 11 817 125 6 182 507 (52·3%) 3 510 756 (29·7%)
Vanuatu 89 478 44 758 (50·0%) 23 599 (26·4%)
Venezuela 12 968 894 4 243 846 (32·7%) 1 269 241 (9·8%)
Vietnam 43 025 626 4 070 306 (9·5%) 2 326 560 (5·4%)
Virgin Islands 53 922 12 913 (23·9%) 3833 (7·1%)
Western Sahara 271 213 149 225 (55·0%) 58 160 (21·4%)
Yemen 7 284 023 3 422 350 (47·0%) 1 424 088 (19·6%)
Zambia 3 950 721 729 005 (18·5%) 275 312 (7·0%)
Zimbabwe 4 064 530 1 092 368 (26·9%) 408 656 (10·1%)
Data are n (%). Based on apnoea-hypopnoea index (AHI) cutoff values of five or more events per h and 15 or more 
events per h.
Table 3: Number of patients with obstructive sleep apnoea and prevalence of obstructive sleep apnoea 
by country
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continent; the country-imputation algorithm does not 
reduce these estimates. Furthermore, logistic regression 
weights all predictor variables equally, whereas the 
country-imputation algorithm weights BMI as the most 
important factor in matching countries, racial distribution 
is a secondary factor, and geographical proximity is only 
used to resolve multiple matches on the first two 
predictors. This weighting of factors allows Australian 
men to be matched to Canadian men, for example, which 
would not be feasible in the logistic regression model. The 
logistic regression model also estimated that Asian 
countries similar to Singapore (BMI 24·2 kg/m², 
9% white) have an obstructive sleep apnoea prevalence of 
16·7%, whereas the country-imputation algorithm 
estimated these countries’ prevalence as being 62·3%, as 
reported by Tan and colleagues.36 These were the major 
drivers for the difference in the global estimate between 
the country-imputation algorithm and the more 
generalised logistic regression model.
Second, we recognise that the parent studies from 
which we derived our estimates also have their own 
limitations, including first night effect, degree of sleep 
deprivation, body position, night to night variability, and 
participation and selection bias. Participation bias is an 
issue with many epidemiological studies and cannot 
easily be addressed with changing study design. Selection 
bias reflects the fact that people who are invited to 
participate might not be representative of the general 
population. This issue is amplified by the reliance on 
convenience samples rather than efforts to make 
sampling truly representative of the broader population. 
In acknowledging this limitation, we hope that new 
technologies will become available that might allow more 
consistent assessments of the general population.
Third, issues around methodological variability are 
clearly important, given the improved sensitivity observed 
with nasal pressure measurements versus with 
thermistor signals alone.41,57 Furthermore, pulse oximeters 
have variable time constraints and thus varying sensitivity 
and specificity for desaturation depending on equipment 
characteristics. Manual scoring of sleep studies is also 
likely to result in interscorer variability, especially in 
scoring arousals, which could affect hypopnea scoring 
and partly explain the variation seen in the published 
prevalence data for obstructive sleep apnoea. Re-scoring 
the raw data from the original studies according to 
consistent criteria would be challenging and 
standardisation of equipment from previous studies is 
not possible. Instead, we attempted to make estimates 
based on these known sources of variance. As a result, 
there are wide confidence intervals around our estimates 
based on strict versus liberal criteria. Nonetheless, we are 
aware that much higher prevalence figures could be 
generated depending on the assumptions used. None of 
the limitations mentioned here were considered in 
calculation of the 95% CIs; these intervals only reflect the 
sampling variability due to the study sizes used to 
estimate obstructive sleep apnoea prevalence. The 
confidence intervals do not reflect uncertainty in the 
obstructive sleep apnoea prevalence estimates for each 
country. The goodness of fit of the country-imputation 
algorithm was assessed as a cross-validation; this analysis 
indicates a potential underestimation of the global 
obstructive sleep apnoea prevalence (of up to –48%). A 
sensitivity analysis, based on a logistic regression model, 
indicated a potential overestimation of up to 28%. 
However, the logistic regression models severely 
underestimated prevalence of obstructive sleep apnoea in 
Singapore, Germany, and Switzerland. Clearly, estimating 
obstructive sleep apnoea prevalence in 193 countries 
based on sleep studies from just 16 countries will be 
subject to some error. These estimates can be refined 
when further data become available. Despite these 
limitations, our findings address an important gap in the 
published literature with regard to reporting 
comprehensive prevalence data for obstructive sleep 
apnoea.
In conclusion, this analysis highlights the high 
worldwide prevalence of obstructive sleep apnoea and 
variations by country and region. Additional, well 
designed studies are needed to investigate the prevalence 
of obstructive sleep apnoea, particularly in countries 
where published data are not available. This high 
prevalence and the documented association between 
obstructive sleep apnoea and numerous adverse clinical 
outcomes, including cardiovascular disease morbidity 
and mortality, mean that health-care systems around the 
world need to consider strategies to raise awareness of 
obstructive sleep apnoea and to diagnose and treat the 
condition to have a positive impact on population health 
and health-care expenditures.
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